Total: 1 |
|
PMID (PMCID) | ||
---|---|---|
24067929 |
FEMALE | Middle Aged |
Reversible bone marrow aplasia induced by pegylated interferon-alpha-2a therapy in a patient with primary myelofibrosis. | ||
Mainali NR, Bhatt VR, Kedia S, Krishnamurthy J, Wake LM, Akhtari M. J Oncol Pharm Pract. 2014;20(5):386-92. |
||
Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-945-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. |